An observational study in Respiratory Failure, Respiratory Insufficiency and Respiratory Tract Diseases, sponsored by Hôpital de Verdun. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-28.
Sponsored by Hôpital de Verdun · Observational
A retrospective cohort study of all patients treated for type II (hypercapnic) respiratory failure with either High-Flow Oxygen Therapy or Non-Invasive Ventilation in a general adult hospital.
We will compare various clinically relevant outcomes in patients treated for type II (hypercapnic) acute respiratory failure (ARF) with either High-Flow Nasal Cannula (HFNC) or Non-Invasive Ventilation (NIV) in a general adult hospital.
All patients treated with HFNC were treated with an Optiflow device (Fisher\&Paykel). Various Bilevel positive airway pressure (BiPAP) devices were used during the study period.
All ventilatory parameters were set according to the treating physicians' preferences.
1,369 studies on the registry are indexed under Respiratory Insufficiency; 264 are open to participants now.
This study's enrollment of 324 is above the median of 100 across 455 observational studies indexed under Respiratory Insufficiency.
Browse Respiratory Insufficiency studies →Hôpital de Verdun is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
All patients treated for respiratory II failure in the hospital, including patients treated on the general medical floors, in the emergency department, and in the intensive-care unit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All patients with type II respiratory failure that were deemed by the treating physician to require ventilatory support either with non-invasive ventilation (NIV) or High-Flow Nasal Cannula (HFNC).
Device: Non-Invasive Ventilation · Device: High-Flow Nasal Cannula
Treatment with Non-Invasive Ventilation by BiPAP. Different BiPAP models are in use. Ventilation parameters set at the discretion of the treating physician.
Also known as: BiPAP
Treatment with a High-Flow Nasal Cannula. The Optiflow device by Fisher\&Paykel used in all cases. Flow and fraction of inspired oxygen (FiO2) parameters at the discretion of the treating physician.
Also known as: HFNC
Failure of initial treatment (combined outcome)
Combined outcome of death or intubation or transition to another treatment modality or unplanned resumption of respiratory support
Time frame: 48 hours post intervention
Death at 48h
Mortality in the 48h following the initial intervention
Time frame: 48 hours post intervention
Mortality at 7d
Incidence of death in the 7 days after intervention
Time frame: 7 days post intervention
Incidence of endotracheal intubation
The incidence of intubation
Time frame: For the whole length of hospital stay, up to a maximum of one year.
Length of stay
Duration of stay in the hospital, in days
Time frame: For the whole length of hospital stay, up to a maximum of one year.
Duration of endotracheal intubation
Duration (in hours) of the first episode of endotracheal intubation, immediately following the failed intervention
Time frame: For the whole length of hospital stay, up to a maximum of one year.
Incidence of intervention change
The incidence of patients who switch from Non-Invasive Ventilation to High-Flow Oxygen, and vice versa, due to treatment failure
Time frame: For the whole length of hospital stay, up to a maximum of one year.
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2015 to primary completion in Jul 2019, 51 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hôpital de Verdun